Role of Transforming Growth Factor Beta 1 in Non Alcoholic Fatty Liver Diabetes Patients

Abstract

Background: Non-alcoholic fatty liver disease [NAFLD] is a spectrum of disease that ranges from simple steatosis to the
more progressive form terms as non-alcoholic steatohepatitis. Diabetes is a group of metabolic diseases characterized by
hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The link between these two diseases is
resistance to insulin and NAFLD is known as liver component of metabolic syndrome. Compensatory hyperinsulinemia
leads to beta cell dysfunction in T2DM and defects in lipid metabolism and hepatic triglyceride accumulation in NAFLD.
Transforming growth factor-β is an anti-inflammatory cytokine which inhibits the activation of macrophages.
Material and Methods: In this study, 100 patients with T2DM and 50 controls, patients with T2DM were enrolled and
among them 50 [50%] subjects were females and 50 [50%] subjects were males. Of the total of 100, 60 [60 %] individuals
had NAFLD. aged between 40-70 years were voluntarily enrolled from a Thi-qar Specialized Diabetes Endocrine and
Metabolism Center [TDEMC] from January 2019 to jun 2019.
Result: TGF. β1 and FBG and HBA1C,TG,TC,LDL-C and VLDL-C levels in the blood showed a significant increase in
NAFLD and normal liver groups as compared to control group [P ≤ 0.05]. While the results of HDL-cholesterol were
observed statistically significant reduction in NAFLD and normal liver groups as compared to control group [P ≤ 0.05].
While no significant difference in values of HBA1C of NAFLD and normal liver.
Conclusion: The results of this study showed that NAFLD is extremely common in patients with T2DM. FBG and
duration of diabetes was significantly higher in the groups of T2DM patients with NAFLD when compared to normal liver
group. TGF. β 1were significantly elevated in both the groups of T2DM patients with and without NAFLD when compared
to controls.